HGH Fragment 176-191 vs Ipamorelin
Moderate Research vs Well Studied
monitor Mechanism-based · 47% Both HGH Fragment 176-191 and Ipamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
HGH Fragment 176-191 Ipamorelin
Weight 1,817.1 Da 711.85 Da
Half-life 15-20 minutes ~2 hours
Chain 16 amino acids 5 amino acids
Type hGH C-terminal fragment (176-191) Growth hormone secretagogue
Key Benefits
HGH Fragment 176-191
01 Stimulates lipolysis without growth hormone side effects
02 Does not affect blood glucose or insulin sensitivity
03 Does not increase IGF-1 levels
04 Selectively targets fat metabolism
05 No impact on bone or organ growth
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Dosing Protocols
HGH Fragment 176-191
250-500mcg / Twice daily (fasted)
Fat loss - Standard 250mcg Twice daily (morning fasted + pre-bed)
Enhanced fat loss 500mcg Twice daily (morning fasted + pre-bed)
Conservative start 250mcg Once daily (morning, fasted)
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Side Effects
HGH Fragment 176-191
Injection site irritation (redness, mild swelling)
Headache, particularly in the first few days
Generally well-tolerated with a favorable safety profile
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Contraindications
Pregnancy or breastfeeding
Active cancer or history of malignancy
WADA prohibited - athletes subject to testing must avoid
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Research Evidence
HGH Fragment 176-191 Ipamorelin
Status Moderate Research Well Studied
References 4 studies 5 studies
Latest 2014 October 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.